Short answer
Atrium Therapeutics, Inc. (RNA) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Atrium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Investor focus: quarterly performance, cash position and development spending disclosed in the attached release
Item EX-99.1 · Exhibit EX-99.1
- First patient dosed in Phase 1/2 Corventis trial for PRKAG2 syndrome, with initial proof-of-concept data expected in the second half of 2027
- Nonclinical ATR 1072 data showed reversal of cardiac glycogen accumulation and improvements in hypertrophy and ECG conduction measures
- Pro-forma cash $293.6M, including $50.0M private-placement proceeds and $15.0M BMS milestone, supporting operations through 2028
- Third-quarter collaboration revenue $15.3M, including a $15.0M BMS milestone payment
- Net loss $4.266M, or $0.25 per share, while R&D expenses increased to $13.796M for clinical and IND-enabling programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Atrium Therapeutics, Inc. 8-K filings
Get the next RNA 8-K as it lands
Follow RNA for push alerts, or ask the research agent what this filing means.